Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American …
DM Nathan, JB Buse, MB Davidson… - Diabetes …, 2009 - Am Diabetes Assoc
The consensus algorithm for the medical management of type 2 diabetes was published in
August 2006 with the expectation that it would be updated, based on the availability of new …
August 2006 with the expectation that it would be updated, based on the availability of new …
Thiazolidinediones
H Yki-Järvinen - New England Journal of Medicine, 2004 - Mass Medical Soc
Despite a large need for new hypoglycemic therapies, given the epidemic of type 2 diabetes,
very few agents have been introduced during the past 20 years. The thiazolidinediones …
very few agents have been introduced during the past 20 years. The thiazolidinediones …
Acetyl CoA carboxylase inhibition reduces hepatic steatosis but elevates plasma triglycerides in mice and humans: a bedside to bench investigation
Inhibiting lipogenesis prevents hepatic steatosis in rodents with insulin resistance. To
determine if reducing lipogenesis functions similarly in humans, we developed MK-4074, a …
determine if reducing lipogenesis functions similarly in humans, we developed MK-4074, a …
The impact of oxidative stress on adipose tissue energy balance
PM Masschelin, AR Cox, N Chernis… - Frontiers in physiology, 2020 - frontiersin.org
Overnutrition and sedentary activity reinforce the growing trend of worldwide obesity, insulin
resistance, and type 2 diabetes. However, we have limited insight into how food intake …
resistance, and type 2 diabetes. However, we have limited insight into how food intake …
Management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American …
DM Nathan, JB Buse, MB Davidson, RJ Heine… - Diabetes …, 2006 - Am Diabetes Assoc
The epidemic of type 2 diabetes in the latter part of the 20th and in the early 21st century,
and the recognition that achieving specific glycemic goals can substantially reduce …
and the recognition that achieving specific glycemic goals can substantially reduce …
Thiazolidinediones and PPARγ agonists: time for a reassessment
Thiazolidinediones (TZDs) are anti-diabetic drugs that act as insulin sensitizers and are
used in the management of type 2 diabetes mellitus. TZDs, which are ligands for the …
used in the management of type 2 diabetes mellitus. TZDs, which are ligands for the …
Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from …
DM Nathan, JB Buse, MB Davidson, E Ferrannini… - Diabetologia, 2009 - Springer
The consensus algorithm for the medical management of type 2 diabetes was published in
August 2006 with the expectation that it would be updated, based on the availability of new …
August 2006 with the expectation that it would be updated, based on the availability of new …
Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association
RW Nesto, D Bell, RO Bonow, V Fonseca, SM Grundy… - Circulation, 2003 - Am Heart Assoc
occur over time during TZD treatment. Patients with type 2 diabetes who have significant
underlying asymptomatic heart disease may also be prescribed these drugs, even though …
underlying asymptomatic heart disease may also be prescribed these drugs, even though …
Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association
RW Nesto, D Bell, RO Bonow, V Fonseca… - Diabetes …, 2004 - cdr.lib.unc.edu
Abstract" Diabetes is a chronic, progressively worsening disease associated with a variety of
microvascular and macrovascular complications. Cardiovascular disease (CVD) is the main …
microvascular and macrovascular complications. Cardiovascular disease (CVD) is the main …
A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia
RB Goldberg, DM Kendall, MA Deeg, JB Buse… - Diabetes …, 2005 - Am Diabetes Assoc
OBJECTIVE—Published reports suggest that pioglitazone and rosiglitazone have different
effects on lipids in patients with type 2 diabetes. However, these previous studies were …
effects on lipids in patients with type 2 diabetes. However, these previous studies were …